MedWatch

Raw materials price spikes will prove costly for the life science industry

Companies such as Coloplast, Novo Nordisk, Ambu and Lundbeck will end up paying for the increasing costs of raw materials, predicts the head of equity research at Carnegie Investment Bank.

Photo: Coloplast / PR

It will to be difficult for the life science industry to pass the rising raw material bill down the line to users as government purchasers are less willing to renegotiate new prices, says Head of Equity Research at Carnegie Investment Bank Niels Granholm-Leth, as reported by Danish business daily Børsen.

"Prices are often decided by various governmental discount programs that aren't regulated often, and so healthcare companies can be hit by falling margins in a period going forward," Granholm-Leth tells Børsen.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs